Pinnacle Peak Institute drug, alcohol treatment professionals utilize the American Society of Addiction Medicine Patient Placement Criteria (ASAM PPC) when making decisions regarding the level of treatment for each individual patient. Pinnacle Peak Institute provides ASAM level I outpatient for patients who have been assessed and deemed appropriate for a lower level of drug, alcohol treatment.
The frequency of group and individual sessions and the length of the treatment episode can vary for each patient. Typically a patient will attend group sessions once or twice weekly and meet in individual sessions with their CDP at least once a month for a minimum of eight weeks.
Each patient must participate in a drug, alcohol assessment before being referred to Outpatient treatment.
The frequency of group and individual sessions and the length of the treatment episode can vary for each patient. Typically a patient will attend group sessions once or twice weekly and meet in individual sessions with their CDP at least once a month for a minimum of eight weeks.
Each patient must participate in a drug, alcohol assessment before being referred to Outpatient treatment.
Pinnacle Peak Institute provides Washington State Certified Intensive Outpatient drug, alcohol treatment services based on an individualized treatment plan for each patient.
Chemical dependency treatment services are designed to meet the unique needs of a population of patients and their families who are being impacted by the disease of Chemical Dependency. PPI treats chemical dependency as a primary, progressive and chronic disease. Chemical dependence is a disease in which the alcohol and/or drugs cause changes in a person’s body, mind, and behavior. This addictive process can lead to physical illness, behavioral problems, mental and emotional problems, serious societal consequences and spiritual bankruptcy.
Patients involved in IOP drug, alcohol treatment will participate in group sessions facilitated by a PPI Chemical Dependency Professional (CDP) three times per week for a minimum of twelve weeks. The patient will also receive individual sessions with their primary CDP a minimum of once a month with additional sessions as clinically appropriate. The patient will also provide random alcohol, drug screenings twice a month at a minimum. Group sessions facilitated by Chemical Professionals (CDP) or Trainees (CDPT) under supervision will be structured, symptom-focused and include a wide variety of skill-building techniques to reduce maladaptive thoughts and behaviors and relapse prevention skills. Information and resources will be provided to help establish understanding of the negative consequences of mood-altering chemicals and the pathway to full recovery.
Chemical dependency treatment services are designed to meet the unique needs of a population of patients and their families who are being impacted by the disease of Chemical Dependency. PPI treats chemical dependency as a primary, progressive and chronic disease. Chemical dependence is a disease in which the alcohol and/or drugs cause changes in a person’s body, mind, and behavior. This addictive process can lead to physical illness, behavioral problems, mental and emotional problems, serious societal consequences and spiritual bankruptcy.
Patients involved in IOP drug, alcohol treatment will participate in group sessions facilitated by a PPI Chemical Dependency Professional (CDP) three times per week for a minimum of twelve weeks. The patient will also receive individual sessions with their primary CDP a minimum of once a month with additional sessions as clinically appropriate. The patient will also provide random alcohol, drug screenings twice a month at a minimum. Group sessions facilitated by Chemical Professionals (CDP) or Trainees (CDPT) under supervision will be structured, symptom-focused and include a wide variety of skill-building techniques to reduce maladaptive thoughts and behaviors and relapse prevention skills. Information and resources will be provided to help establish understanding of the negative consequences of mood-altering chemicals and the pathway to full recovery.